Type 1 diabetes mellitus (T1DM) is characterized by a loss of β-cells in the islets of Langerhans of the pancreas and subsequent deficient insulin secretion in response to hyperglycemia. Development of an in vivo test to measure β-cell mass (BCM) would greatly enhance the ability to track diabetes therapies. β-cells and neurologic tissues have common cellular receptors and transporters, therefore, we screened brain radioligands for their ability to identify β-cells. Methods: We examined a β-cell gene atlas for endocrine pancreas receptor targets and cross-referenced these targets with brain radioligands that were available at our institution. Twelve healthy control subjects and 2 T1DM subjects underwent dynamic PET/CT scans with 6 tracers. Results: The D2/D3 receptor agonist radioligand 11C-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) was the only radioligand to demonstrate sustained uptake in the pancreas with high contrast versus abdominal organs such as the kidneys, liver, and spleen, based on the first 30 min of data. Mean SUV from 20 to 30 min demonstrated high uptake of 11C-(+)-PHNO in healthy controls (SUV, 13.8) with a 71% reduction in a T1DM subject with undetectable levels of C-peptide (SUV, 4.0) and a 20% reduction in a T1DM subject with fasting C-peptide level of 0.38 ng/mL (SUV, 11.0). SUV in abdominal organs outside the pancreas did not show measurable differences between the control and T1DM subjects, suggesting that the changes in SUV of 11C-(+)-PHNO may be specific to changes in the pancreas between healthy controls and T1DM subjects. When D3 and D2 antagonists were used in nonhuman primates, specific pancreatic binding (SUVR-1) of 11C-PHNO was reduced by 57% and 38%, respectively. Conclusion: 11C-(+)-PHNO is a potential marker of BCM, with 2:1 binding of D3 receptors over D2 receptors. Further in vitro and in vivo studies to establish D2/D3 receptor specificity to β-cells is warranted to characterize 11C-(+)-PHNO as a candidate for clinical measurement of BCM in healthy control and diabetic subjects.
Type 1 diabetes mellitus (T1DM) is characterized by a loss of β-cells in the islets of Langerhans of the pancreas and subsequent deficient insulin secretion in response to hyperglycemia. Development of an in vivo test to measure β-cell mass (BCM) would greatly enhance the ability to track diabetes therapies. β-cells and neurologic tissues have common cellular receptors and transporters, therefore, we screened brain radioligands for their ability to identify β-cells. Methods: We examined a β-cell gene atlas for endocrine pancreas receptor targets and cross-referenced these targets with brain radioligands that were available at our institution. Twelve healthy control subjects and 2 T1DM subjects underwent dynamic PET/CT scans with 6 tracers. Results: The D2/D3 receptor agonist radioligand 11C-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) was the only radioligand to demonstrate sustained uptake in the pancreas with high contrast versus abdominal organs such as the kidneys, liver, and spleen, based on the first 30 min of data. Mean SUV from 20 to 30 min demonstrated high uptake of 11C-(+)-PHNO in healthy controls (SUV, 13.8) with a 71% reduction in a T1DM subject with undetectable levels of C-peptide (SUV, 4.0) and a 20% reduction in a T1DM subject with fasting C-peptide level of 0.38 ng/mL (SUV, 11.0). SUV in abdominal organs outside the pancreas did not show measurable differences between the control and T1DM subjects, suggesting that the changes in SUV of 11C-(+)-PHNO may be specific to changes in the pancreas between healthy controls and T1DM subjects. When D3 and D2 antagonists were used in nonhuman primates, specific pancreatic binding (SUVR-1) of 11C-PHNO was reduced by 57% and 38%, respectively. Conclusion:11C-(+)-PHNO is a potential marker of BCM, with 2:1 binding of D3 receptors over D2 receptors. Further in vitro and in vivo studies to establish D2/D3 receptor specificity to β-cells is warranted to characterize 11C-(+)-PHNO as a candidate for clinical measurement of BCM in healthy control and diabetic subjects.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Mika Naganawa; Shu-Fei Lin; Keunpoong Lim; David Labaree; Jim Ropchan; Paul Harris; Yiyun Huang; Masanori Ichise; Richard E Carson; Gary W Cline Journal: Nucl Med Biol Date: 2016-09-02 Impact factor: 2.408
Authors: Yoshifumi Saisho; Paul E Harris; Alexandra E Butler; Ryan Galasso; Tatyana Gurlo; Robert A Rizza; Peter C Butler Journal: J Mol Histol Date: 2008-09-13 Impact factor: 2.611
Authors: Marc D Normandin; Kitt F Petersen; Yu-Shin Ding; Shu-Fei Lin; Sarita Naik; Krista Fowles; Daniel M Skovronsky; Kevan C Herold; Timothy J McCarthy; Roberto A Calle; Richard E Carson; Judith L Treadway; Gary W Cline Journal: J Nucl Med Date: 2012-05-09 Impact factor: 10.057
Authors: Maria Jose Garcia Barrado; Maria Carmen Iglesias Osma; Enrique J Blanco; Marta Carretero Hernández; Virginia Sánchez Robledo; Leonardo Catalano Iniesta; Sixto Carrero; Jose Carretero Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240
Authors: Juris J Meier; Bjoern A Menge; Thomas G K Breuer; Christophe A Müller; Andrea Tannapfel; Waldemar Uhl; Wolfgang E Schmidt; Henning Schrader Journal: Diabetes Date: 2009-06-09 Impact factor: 9.461
Authors: Martha L Campbell-Thompson; Stephanie L Filipp; Joseph R Grajo; Bimota Nambam; Richard Beegle; Erik H Middlebrooks; Matthew J Gurka; Mark A Atkinson; Desmond A Schatz; Michael J Haller Journal: Diabetes Care Date: 2018-12-14 Impact factor: 19.112
Authors: Jason Bini; Elizabeth Sanchez-Rangel; Jean-Dominique Gallezot; Mika Naganawa; Nabeel Nabulsi; Keunpoong Lim; Soheila Najafzadeh; Anupama Shirali; Jim Ropchan; David Matuskey; Yiyun Huang; Kevan C Herold; Paul E Harris; Robert S Sherwin; Richard E Carson; Gary W Cline Journal: J Nucl Med Date: 2019-10-10 Impact factor: 11.082